The Incretin Revolution

Introduction: The Incretin Concept and the Dawn of a New Paradigm

The transformation of glucagon-like peptide-1 (GLP-1) from an obscure gastrointestinal hormone to the foundational target of successful pharmacological interventions in modern medicine represents a major achievement of basic science, chemical engineering, and strategic drug development. The "incretin effect" — the physiological phenomenon wherein orally ingested glucose elicits a substantially greater insulin response than an equivalent dose of intravenous glucose — was first hypothesized in the early twentieth century. However, the translation of this biological mechanism into viable therapies required decades of molecular research to overcome the profound pharmacokinetic limitations of native human peptides.

By 2026, the incretin pharmaceutical class has evolved beyond the boundaries of glycemic control in type 2 diabetes mellitus (T2DM). These therapies have redefined the treatment protocols for obesity, demonstrating cardiovascular disease risk reduction, mitigating the progression of chronic kidney disease (CKD), and establishing new therapeutic avenues for metabolic dysfunction-associated steatohepatitis (MASH) and obstructive sleep apnea. The class has also attracted AI-driven drug discovery approaches targeting novel oral incretin agonists and complementary longevity therapeutics. This report delineates the chronological history of incretin research, evaluating the target discovery phase, the pharmaceutical competition that led to successes for Novo Nordisk and Eli Lilly, the strategic and clinical failures of competitors including Pfizer, Sanofi, and GlaxoSmithKline, and the evolving epidemiological data of GLP-1 adverse events at the population level.

Target Discovery and the Molecular Biological Era

The Early Search for Incretins (1906 to 1970s)

The scientific journey of GLP-1 began with early observations of gut-pancreas endocrinology, long before the molecular tools existed to fully interrogate the relationship. In 1906, Moore and colleagues in Liverpool demonstrated that extracts derived from the intestine could lower blood glucose when administered to subjects, suggesting the presence of a gut-derived hypoglycemic factor. The pursuit of this factor waned with the discovery of insulin but was revitalized in 1929 when Belgian researchers J. La Barre and E. Zunz confirmed that an intestinal factor actively enhanced pancreatic insulin secretion. In 1932, La Barre formally coined the term "incretin" (derived from INtestine seCRETion INsulin) to describe this specific endocrine action. For decades, the incretin hypothesis languished in controversy due to the lack of precise biochemical assays capable of measuring the minute concentrations of circulating hormones.

The concept was resurrected and empirically validated in the 1960s following a critical technological breakthrough: the invention of the radioimmunoassay by Rosalyn Yalow and Solomon Berson in 1960, which allowed for the precise quantification of plasma insulin levels. Leveraging this new tool, researchers H. Elrick, N. McIntyre, J.E. Perley, and D.M. Kipnis independently published data in 1964 demonstrating the first quantitative evidence of the incretin effect in humans. They proved that oral glucose triggered a vastly superior and more rapid insulin response compared to intravenous glucose administration, despite identical blood glucose concentrations being achieved. This physiological observation catalyzed the search for the specific gastrointestinal hormones responsible. Gastric Inhibitory Polypeptide (GIP) was identified in 1971 by Brown and colleagues and was initially championed as the primary incretin hormone. However, subsequent clinical trials revealed a critical flaw: GIP rapidly loses its insulinotropic effectiveness in patients with T2DM, indicating that while it contributes to the incretin effect in healthy individuals, another, more potent incretin hormone must exist to account for the total physiological response.

Cloning the Proglucagon Gene and Identifying GLP-1 (1980s)

The definitive identification of GLP-1 occurred in the early 1980s, propelled by the advent of recombinant DNA technology. In the late 1970s, endocrinologist Joel Habener established his laboratory at Massachusetts General Hospital with the primary goal of identifying the precursor molecules to pancreatic glucagon and somatostatin. Constrained by a National Institutes of Health moratorium on recombinant DNA research in warm-blooded animals, Habener and his colleagues, P. Kay Lund and Richard H. Goodman, creatively circumvented the restriction by utilizing the unique pancreas of the anglerfish, supplied by a local commercial fisherman. In 1982, Habener's laboratory successfully isolated the cDNA encoding proglucagon and reported that the fish glucagon gene encodes a larger precursor protein containing both glucagon and a second, structurally similar peptide.

Habener's lab circumvented a federal moratorium on recombinant DNA research in warm-blooded animals by cloning proglucagon from anglerfish pancreata supplied by a local commercial fisherman. — The unusual origin story of GLP-1, 1982

Simultaneously, in 1983, Graeme Bell at the Chiron Corporation cloned the hamster proglucagon gene, confirming that mammals also possessed this highly conserved sequence, which he formally named glucagon-like peptide-1 (GLP-1). While the genetic sequence was now known, the specific biologically active form of the hormone circulating in the human body remained a mystery. At The Rockefeller University, peptide chemist Svetlana Mojsov dedicated her research to identifying the specific physiological cleavage product of this precursor. Mojsov chemically synthesized various fragments of the sequence and developed highly specific antibodies to trace their presence in biological tissues. She definitively determined that a truncated version of the molecule, specifically GLP-1(7-37), was the biologically active incretin liberated from the longer precursor in the mammalian gut. Utilizing the isolated perfused pancreas model, Mojsov and her collaborator Gordon Weir proved that GLP-1(7-37) potently stimulated insulin secretion at remarkably low physiological concentrations of 50 pM.

Concurrently, Danish physiologist Jens Juul Holst mapped the physiological pathways of the hormone, demonstrating that the luminal presence of glucose directly stimulated the endogenous secretion of GLP-1 from intestinal L-cells located in the distal ileum and colon. Furthermore, endocrinologist Daniel Drucker contributed significantly to characterizing the hormone's expansive mechanism of action, elucidating its profound effects on delaying gastric motility, suppressing postprandial glucagon secretion, and signaling satiety within the central nervous system. For these foundational discoveries, Habener, Mojsov, Holst, Drucker, and later pharmaceutical scientists were rightfully recognized with the highest accolades in biomedical science, including the Warren Alpert Foundation Prize, the Breakthrough Prize in Life Sciences in 2025, and the Lasker~DeBakey Clinical Medical Research Award in 2024.

The Gila Monster Connection and the DPP-4 Barrier (Early 1990s)

While GLP-1(7-37) was highly effective in stimulating glucose-dependent insulin secretion, its early clinical translation was completely halted by a massive pharmacokinetic hurdle: native human GLP-1 possesses a half-life of roughly 1.5 to 2 minutes in human plasma. This extraordinarily rapid clearance is driven by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-4), which specifically targets and cleaves peptides containing a position-two alanine or proline, rendering the GLP-1 molecule inactive almost immediately upon secretion, followed by rapid renal filtration.

A critical breakthrough for therapeutic development emerged from an entirely unexpected biological source. In the early 1990s, Dr. Jean-Pierre Raufman, a researcher at the National Institutes of Health, and biochemist John Eng discovered that the venomous saliva of the Gila monster (Heloderma suspectum), a desert reptile, contained a unique peptide that bound with high affinity to the mammalian GLP-1 receptor. This 39-amino acid peptide, named exendin-4, shared roughly 50% sequence homology with human GLP-1 but possessed a critical structural difference at the N-terminus (a glycine substitution), making it entirely resistant to DPP-4 enzymatic degradation. Exendin-4 maintained an extended half-life in human circulation, providing the structural blueprint for exenatide, the first-in-class GLP-1 receptor agonist (GLP-1RA), and proving definitively that structural modification of the peptide sequence could yield viable, long-acting metabolic therapeutics for chronic disease management.

The Pharmaceutical Race: Historic Failures and Exits

The transition from identifying the GLP-1 target to establishing a commercially viable therapeutic class was fraught with technical and strategic challenges. The modern incretin market is heavily consolidated, functioning effectively as a duopoly between Novo Nordisk and Eli Lilly. However, this consolidation occurred only after several pharmaceutical companies failed to capitalize on early leads, misjudged the pharmacology, or produced chemically inferior formulations that could withstand market competition.

Pfizer: The 1990 Abandonment

Pfizer's involvement with GLP-1 represents a notable missed opportunity in the history of metabolic biotechnology. In 1987, Dr. Jeffrey Flier, alongside John Baxter, founded Metabolic Biosystems (MetaBio) in California to explicitly explore the therapeutic potential of peptide hormones. MetaBio achieved a major clinical milestone by demonstrating for the first time that continuous intravenous infusions of GLP-1(7-37) effectively eliminated postprandial glucose excursions in human subjects with diabetes. Recognizing the potential, MetaBio secured a development partnership with Pfizer.

However, in 1990, Pfizer abruptly terminated the collaboration and abandoned the GLP-1 project. This decision was driven by imperfect information and strategic misallocation of resources. At the time, the two-minute half-life of the native peptide seemed an insurmountable barrier to commercialization, and the critical concept of utilizing fatty acid acylation or DPP-4 resistant analogs had not yet been fully realized. Pfizer executives rationally, but incorrectly, chose to focus their research and development budgets on other, traditional small-molecule antidiabetic mechanisms that were further along in their pipeline. Compounding the issue, because the human efficacy data and preliminary research remained proprietary under the Pfizer contract, the findings could not be freely shared with the broader academic community, inadvertently setting back global commercial GLP-1 development by several years.

Pfizer's Collapse and the Oral GLP-1 Race (2018 to 2026)

Decades after their initial exit, having witnessed the growth of the injectable incretin market, Pfizer attempted to re-enter the space by leapfrogging the injectable market entirely. They aimed to dominate the next frontier: non-peptide, oral small-molecule GLP-1 receptor agonists. This race pitted Pfizer against Eli Lilly and Roche, culminating in a series of strategic errors and clinical failures.

Pfizer's flagship effort was danuglipron (PF-06882961). The program originated from a sensitized high-throughput screen conducted by Pfizer's internal medicinal chemistry team, which successfully identified 5-fluoropyrimidine-based GLP-1R agonists. These were meticulously optimized to activate the receptor in a manner similar to native peptides while remaining orally bioavailable. The program was aggressively championed by Pfizer's internal leadership, including Chief Scientific Officer Mikael Dolsten and Senior Vice President of Internal Medicine William Sessa. Under Pfizer's strict "Signs of Clinical Activity" (SOCA) framework, a stage-gate system designed to revitalize their R&D pipeline, danuglipron was identified as a priority. Because it showed strong Early Signals of Efficacy (ESOE), executives accelerated its development timeline by 12 months, hoping to beat competitors to the oral market.

Simultaneously, a Japanese drugmaker, Chugai Pharmaceutical, had discovered its own oral small-molecule GLP-1, known as OWL833. Chugai operates under a long-standing partnership with the Swiss pharmaceutical company Roche, which held a formal "right of first refusal" for the global development and marketing of any Chugai-originated compounds. However, in 2018, as OWL833 prepared to enter early Phase 1 trials, Roche executives made a historical miscalculation by passing on the drug. Roche's reluctance stemmed from its previous costly failures in the diabetes space, specifically the abandoned taspoglutide program, and a broader skepticism about the commercial viability of obesity therapeutics at the time, as the scientific knowledge of GLP-1 applications was not as advanced.

With Roche stepping aside, Eli Lilly acquired the worldwide rights to OWL833 for a $50 million upfront payment in 2018. This molecule became orforglipron.

Roche passed. Pfizer pushed. Lilly paid $50 million. A decade later, orforglipron became Foundayo — the first food-independent oral GLP-1 obesity pill.

This set the stage for a clinical competition between Pfizer's danuglipron and Lilly's orforglipron. Initially, Pfizer's Phase 2b data for twice-daily danuglipron in adults with obesity was efficacious, achieving 8% to 13% weight reductions at 32 weeks. However, the tolerability was poor. The trial saw severe gastrointestinal side effects resulting in a discontinuation rate of over 50% across all active dose cohorts. Refusing to abandon the molecule, Pfizer halted the twice-daily formulation's progression to Phase 3 and pivoted to dose-optimization studies for a once-daily extended-release version, hoping it would smooth out the pharmacokinetic peaks causing the nausea.

This attempt collapsed in 2025. While pharmacokinetic goals were met, a participant in the once-daily optimization study experienced asymptomatic but significant drug-induced liver injury during the rapid dose titration phase. Having already scrapped a sister oral drug (lotiglipron) in 2023 for similar transaminase elevations, Pfizer was forced to permanently discontinue danuglipron. In early 2024, Pfizer abandoned a third candidate (PF-06954522), effectively ending their obesity pipeline and cementing a second historic failure in the GLP-1 space.

Conversely, Eli Lilly's $50 million bet proved successful. Orforglipron demonstrated high efficacy in mid-stage trials without the severe liver toxicity that doomed Pfizer's candidates. With Pfizer eliminated, Lilly's orforglipron, the drug Roche passed on, was left unchallenged as the preeminent small-molecule oral GLP-1, culminating in its 2026 FDA approval as Foundayo, the first food-independent oral GLP-1 obesity pill.

AstraZeneca, GlaxoSmithKline, and Sanofi: The Perils of Inferior Formulations

Other major pharmaceutical companies successfully brought GLP-1 therapies to market but ultimately failed due to inferior pharmacokinetic profiles and cumbersome delivery mechanisms that could not compete with the optimized formulations from Novo Nordisk and Eli Lilly.

AstraZeneca, through its acquisition of Amylin Pharmaceuticals, brought the very first GLP-1RA, Byetta (exenatide), to market in 2005. Derived directly from Gila monster venom, Byetta required twice-daily subcutaneous injections and was associated with significant peaks in plasma concentration that induced severe nausea. When Novo Nordisk launched the once-daily liraglutide (Victoza) in 2010, Byetta rapidly lost market share. AstraZeneca attempted to recover by developing Bydureon, a once-weekly extended-release formulation of exenatide approved in 2012. However, the formulation suffered from a highly complex, multi-step reconstitution process using large-gauge needles to inject microspheres, leading to painful injection site reactions. In head-to-head clinical trials against newer, ready-to-use liquid formulations like dulaglutide (Trulicity) and semaglutide (Ozempic), Bydureon demonstrated inferior glycemic control and poor patient adherence, ultimately fading from relevance.

GlaxoSmithKline (GSK) suffered a similarly prominent commercial failure with albiglutide (Tanzeum). Approved in 2014, albiglutide was a once-weekly injection engineered by fusing two copies of modified GLP-1 to human albumin. Despite the weekly dosing convenience, albiglutide produced relatively modest HbA1c reductions compared to its peers and was plagued by significant gastrointestinal side effects. GSK struggled to gain formulary access and market traction, eventually withdrawing the drug globally in 2017 entirely for commercial reasons. In a twist of irony, shortly after its withdrawal, the results of the Harmony Outcomes trial (2018) were published, proving that albiglutide conferred a highly significant 22% reduction in major adverse cardiovascular events. Despite this proven cardiovascular benefit, a class effect that would soon become highly prized, GSK maintained its exit, missing out on the subsequent explosion of the cardiovascular-metabolic market.

Sanofi faced setbacks with lixisenatide (Lyxumia/Adlyxin). A once-daily exendin-4 analog, lixisenatide was primarily effective at blunting postprandial glucose spikes rather than lowering fasting glucose. In 2013, while pursuing US approval, Sanofi withdrew its New Drug Application (NDA) from the FDA. The FDA had mandated cardiovascular outcome data to rule out ischemic risks, and Sanofi feared that releasing interim data from their ongoing ELIXA trial to satisfy the regulators would compromise the blinding and statistical integrity of the expensive study. By the time lixisenatide was finally approved in the US in 2016, the once-daily market had been entirely superseded by once-weekly formulations, rendering Sanofi's drug commercially obsolete upon launch. Furthermore, Sanofi completely exited diabetes and cardiovascular research in 2019 and 2020, returning the rights for a next-generation asset, efpeglenatide, to Hanmi Pharmaceutical. Shortly after this return, the AMPLITUDE-O trial proved efpeglenatide significantly reduced cardiovascular and renal events, demonstrating a strategic failure where a company abandoned an asset right before its clinical validation.

Novo Nordisk and Eli Lilly: Success and Market Dominance

The stabilization and subsequent exponential growth of the modern incretin market is fundamentally sustained by the successes of Novo Nordisk and Eli Lilly. Both companies utilized distinct scientific philosophies — optimized acylation versus poly-agonism — to reshape global healthcare.

Novo Nordisk: Pioneers of Acylation and Obesity Prioritization

Novo Nordisk's success was driven by a combination of scientific perseverance and forward-looking executive leadership that refused to accept the prevailing dogma regarding obesity. In the late 1990s, Chief Scientific Officer Mads Krogsgaard Thomsen aggressively advocated for pursuing obesity as a primary therapeutic indication for GLP-1 development. This was a highly controversial stance, as the contemporary pharmaceutical establishment widely viewed obesity as a behavioral issue of caloric surplus rather than a chronic, biologically mediated metabolic disease.

The technical breakthrough required to make GLP-1 a viable chronic treatment came from Lotte Bjerre Knudsen and a team of "repurposed" small-molecule chemists, including Thomas Kruse and Jesper Lau. Tasked with extending the native hormone's two-minute half-life to something clinically useful, Knudsen's team abandoned attempts to alter the peptide sequence extensively and instead utilized a novel chemical approach: fatty acid acylation. By attaching a C16 fatty acid to the GLP-1 peptide via a specific linker at the lysine 26 position, the resulting molecule could bind non-covalently to circulating human serum albumin. This albumin binding created a large molecular complex that acted as a protective shield, preventing rapid renal filtration and physically blocking the access of the DPP-4 enzyme, thereby keeping the drug circulating in the body.

This acylation technology birthed liraglutide (Victoza), which achieved a 13-hour half-life allowing for convenient once-daily dosing. Demonstrating proof-of-concept, Novo Nordisk successfully gained approval for a higher-dose formulation of liraglutide, branded as Saxenda, which became the first GLP-1RA specifically approved for chronic weight management in 2014, yielding an average weight loss of approximately 7% to 9%.

Compound number 217 proved to be the optimal structure. Semaglutide featured a longer fatty di-acid chain and a specific amino acid substitution that extended its half-life to 165 hours, enabling once-weekly administration. — Inside the discovery of semaglutide, Novo Nordisk

However, the true paradigm shift occurred with the development of semaglutide. Seeking to optimize the acylation technique, Kruse, Lau, and Knudsen synthesized hundreds of variants to balance half-life, optimal receptor potency, and physical stability. Compound number 217 proved to be the optimal structure. Semaglutide featured a longer fatty di-acid chain and a specific amino acid substitution that extended its half-life to 165 hours, enabling once-weekly administration. Approved for diabetes as Ozempic in 2017 and for obesity as Wegovy in 2021, semaglutide demonstrated high weight loss efficacy of approximately 15% of body weight, cementing Novo Nordisk as the undisputed pioneer of the metabolic space. In 2025, Novo continued to innovate the delivery mechanism, launching an oral tablet formulation of Wegovy (25mg) utilizing an absorption enhancer (SNAC) to allow gastric absorption of the large peptide, and successfully secured landmark FDA label expansions for Wegovy to reduce major adverse cardiovascular events and the progression of chronic kidney disease. Looking to the future, Novo advanced CagriSema, a fixed-dose combination of semaglutide and the long-acting amylin analog cagrilintide, into late-stage trials in 2026, with market analysts projecting peak sales exceeding $17.2 billion by 2032.

Eli Lilly: Poly-Agonism and Strategic Expansion

While Novo Nordisk perfected the optimization of the single GLP-1 receptor agonist, Eli Lilly utilized multi-receptor pharmacology, internal operational overhauls, and aggressive commercial strategy, ultimately surpassing Novo Nordisk to achieve a $1 trillion market capitalization by 2026.

Lilly's foundational success in this domain traces back to the pioneering peptide chemistry of Dr. Richard DiMarchi. As Group Vice President of Endocrine Research at Lilly in the 1990s, DiMarchi advanced critical insulin analogs (such as Humalog) and established the basic science framework for chemical modifications of protein drugs. Later, transitioning to academia at Indiana University and co-founding biotech startups like Marcadia (which Lilly subsequently acquired), DiMarchi collaborated with researchers like Matthias Tschöp. Together, they hypothesized that targeting multiple neuroendocrine pathways simultaneously, specifically combining GLP-1, GIP, and glucagon receptor agonism, would yield synergistic metabolic benefits vastly superior to single-receptor targeting. This concept of "poly-agonism" became the bedrock of Lilly's modern pipeline.

This scientific vision was operationalized and brought to market under the leadership of Eli Lilly's current scientific executive team, notably Chief Scientific Officer Dan Skovronsky, Group Vice President of Molecule Discovery Andrew Adams, and Group Vice President of Diabetes and Metabolic Research Ruth Gimeno. Dan Skovronsky overhauled Lilly's internal R&D culture by focusing intensely on speed and bypassing traditional bureaucratic hurdles. Under his leadership, the company created an autonomous unit dubbed the "GIP Bio" board, which was granted its own budget and the authority to make rapid decisions. Ruth Gimeno, who joined Lilly from Pfizer in 2011, helped lead this team and spearheaded the early clinical development of tirzepatide (Mounjaro/Zepbound). Tirzepatide is a meticulously engineered "twincretin", a single 39-amino acid peptide that integrates both GIP and GLP-1 receptor agonism.

Lilly's clinical trial strategy was bold. Rather than comparing tirzepatide to a placebo, the massive SURPASS (diabetes) and SURMOUNT (obesity) clinical trial programs explicitly ran head-to-head superiority trials against Novo Nordisk's flagship semaglutide. Tirzepatide proved undeniably superior. In the SURPASS-2 trial, 60% of patients taking the highest dose of tirzepatide achieved the rigorous composite endpoint of an HbA1c below 6.5% coupled with >10% weight loss, without severe hypoglycemia, compared to only 22% of patients taking semaglutide. In obesity trials (SURMOUNT-5), tirzepatide demonstrated a significant weight reduction of approximately 22.5%.

Eli Lilly's supremacy in 2026 is underpinned by three strategic pillars beyond clinical efficacy:

Pipeline Dominance through Escalating Agonism

Moving beyond dual agonism, Adams and Gimeno rapidly advanced retatrutide, a triple agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously. In late 2025, Phase 3 results for retatrutide showed a 28.7% mean weight loss, approaching the efficacy of bariatric surgery, alongside profound reductions in liver fat. Furthermore, Lilly advanced orforglipron, a highly effective non-peptide oral GLP-1 agonist, which received FDA approval as Foundayo in 2026, fundamentally threatening the injectable market.

Manufacturing Scale

Anticipating the immense global demand and learning from the severe supply chain shortages that crippled the market in 2022 and 2023, Lilly committed $50 billion to manufacturing infrastructure investments between 2020 and 2026. This aggressive capital allocation allowed Lilly to out-produce competitors and capture leading market share in total prescriptions.

Intellectual Property "Patent Thickets"

Employing a highly financialized business model, Lilly aggressively extended its market exclusivity to maximize shareholder return. Analysis reveals a thicket of patents surrounding tirzepatide; Lilly filed over 53 U.S. patent applications, securing protections not just on the core molecule, but heavily patenting minor modifications in delivery devices, extended-release formulations, and specific methods-of-treatment. While the main compound patent expires in 2036, these follow-on patents extend total protection until 2041, effectively barring generic competition and maintaining the high list prices (roughly $1,000 per month) that drive the company's trillion-dollar valuation.

Novel Architectures from Competitors (2025 to 2026)

While Novo and Lilly dominate, other firms are advancing novel incretin architectures to capture niche markets. Amgen rapidly advanced MariTide (maridebart cafraglutide, AMG 133) into the massive Phase 3 MARITIME clinical program. MariTide represents a highly differentiated modality, as it is a bispecific peptide-antibody conjugate that activates the GLP-1 receptor while simultaneously blocking the GIP receptor (GIPR antagonism), exploring an opposing pharmacological theory to Lilly's tirzepatide. Crucially, the antibody conjugation extends the half-life so profoundly that MariTide is dosed via subcutaneous injection only once a month, or even quarterly, addressing the chronic adherence issues associated with weekly injections.

Similarly, Boehringer Ingelheim, in collaboration with Zealand Pharma, advanced survodutide, a dual glucagon/GLP-1 receptor agonist. In the Phase 3 SYNCHRONIZE-1 trial reported in early 2026, survodutide achieved an average weight loss of 16.6% to 17.8 kg after 76 weeks. Because of the glucagon receptor agonism, survodutide specifically promotes hepatic fat oxidation and energy expenditure, leading the FDA to grant it Breakthrough Therapy designation for the treatment of moderate-to-advanced MASH.

Small Molecules, Combinations, and Lifestyle Medicine

Peptide therapeutics require complex manufacturing infrastructure and are typically administered via subcutaneous injection. Small molecule non-peptide agonists offer major manufacturing advantages, lowering the cost of goods sold and allowing for global scaling. For patients, oral small molecules eliminate the pain of injections and the strict fasting requirements associated with peptide pills like oral semaglutide. The clinical competition to dominate this oral space was fiercely contested between Pfizer's danuglipron and Eli Lilly's orforglipron. Pfizer's danuglipron demonstrated efficacy but suffered from severe gastrointestinal intolerability and subsequent drug-induced liver injury, forcing Pfizer to abandon the once-daily optimization program in 2025. Eli Lilly's orforglipron, originating from Chugai Pharmaceutical, maintained a favorable safety profile and demonstrated significant weight reduction. With the FDA approval of orforglipron (branded as Foundayo) in 2026, the focus of obesity treatment shifted toward accessible daily pills that do not require fasting restrictions.

With the oral baseline established, pharmaceutical companies are accelerating the development of multi-receptor agonists to improve safety, increase optionality in dosing, and drive greater weight loss. The most advanced architecture is the GGG triple agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. Eli Lilly's retatrutide represents the peak of this approach, achieving near 29 percent weight loss in clinical trials. The addition of glucagon receptor agonism specifically promotes hepatic fat oxidation and increases basal energy expenditure, counteracting the metabolic slowdown typically seen with large weight reduction.

The success of incretin therapies has created a new therapeutic category: lifestyle and longevity medicine. Researchers now view GLP-1 analogs as foundational treatments for extending human healthspan, supported by data showing significant reductions in major cardiovascular events and the prevention of chronic disease progression. However, large-scale evidence demonstrating that incretins can explicitly reverse validated methylation or proteomic aging clocks in healthy populations remains preliminary, despite strong proteomic shifts observed in major outcome trials.

Flush with capital from incretin sales, major companies are directing investments into large, previously untractable markets:

Muscle Wasting. A major concern with GLP-1 induced weight loss is the concurrent loss of lean muscle mass. To combat this, companies are exploring muscle preserving agents. BioAge Labs advanced azelaprag, an apelin receptor agonist designed to mimic the biological effects of exercise, though its Phase 2 STRIDES trial was discontinued in late 2024 due to liver transaminitis. Eli Lilly acquired Versanis Bio to advance bimagrumab, an antibody targeting type II activin receptors, navigating complex trial designs to optimize clinical efficacy.

Ophthalmology. Pharmaceutical companies are utilizing their new capital to enter gene therapy and ophthalmology. Driven by Andrew Adams, Group Vice President of Molecule Discovery, Eli Lilly established a $475 million strategic collaboration with MeiraGTx to develop ocular gene therapies. This partnership focuses on AAV-AIPL1 for severe inherited retinopathies (LCA4) and explores using proprietary riboswitch technology for the regulated delivery of metabolic peptides directly to the eye.

Bone Health. The role of incretins extends deeply into skeletal architecture. Basic science research demonstrates that GIP receptor agonism plays a central role in bone metabolism. GIP actively reduces bone resorption by suppressing the marker CTX-I and stimulates bone formation by increasing the marker P1NP, offering a potential therapeutic avenue for age-related bone density loss.

Sleep Management. The systemic benefits of weight reduction have provided direct interventions for sleep disorders. Based on the SURMOUNT-OSA trial, which showed up to 51.5 percent of participants meeting the criteria for disease resolution, tirzepatide secured FDA approval for the treatment of moderate-to-severe obstructive sleep apnea, directly linking incretin therapy to improvements in sleep quality, daytime somnolence, and the mitigation of apnea-related cardiovascular risks.

The application of artificial intelligence to GLP-1 drug design has also emerged as a frontier. In November 2025, Insilico Medicine disclosed eight oral small-molecule cardiometabolic programs designed with its Pharma.AI platform, including a fully biased oral GLP-1R agonist intended for once-weekly dosing. The portfolio, spanning lead identification to IND-enabling stages, represents a convergence of generative AI-driven chemistry with the incretin mechanism, potentially offering new routes to oral bioavailability and combination optimization.

Population Level Adverse Events and Regulatory Safety Warnings

As incretin mimetics transitioned from niche endocrinology treatments to ubiquitous lifestyle and anti-obesity medications used by tens of millions of individuals globally, post-market pharmacovigilance unveiled a highly complex safety profile. Regulatory bodies, primarily the FDA and the EMA, were forced to repeatedly update labeling requirements to reflect emerging real-world data and mitigate severe population-level risks.

Early Gastrointestinal Intolerability and the Pancreatitis Scare (2005 to 2015)

Upon the initial commercial launch of short-acting agents like exenatide and early daily agents like liraglutide, the most prevalent adverse events were overwhelmingly gastrointestinal in nature. Nausea, vomiting, diarrhea, and constipation affected up to 50% to 60% of patients during the initial dose titration phases. While these symptoms were generally transient and dose-dependent, they represented the primary cause of therapy discontinuation in the real world.

However, far more severe physiological signals quickly emerged. Because GLP-1 receptors are highly expressed in the exocrine tissue of the pancreas, early post-marketing safety databases suggested a potential correlation between GLP-1RA use and an increased incidence of acute pancreatitis and, subsequently, pancreatic cancer. In 2013, a publicized investigation broadcasted on television and detailed in the British Medical Journal and JAMA sparked global medical alarm, alleging that the pharmaceutical industry was actively suppressing data regarding drug-induced pancreatic damage. This media scrutiny triggered emergency clinical reviews by both the FDA and the EMA. Ultimately, comprehensive nationwide audits (such as the ABCD audits in the UK) and extensive, multi-year cardiovascular outcome trials (CVOTs) definitively proved that the incidence of pancreatitis and pancreatic cancer among GLP-1RA users was statistically indistinguishable from placebo comparator groups, effectively dispelling the concerns and preserving the drug class.

Thyroid C-Cell Tumors and Boxed Warnings (2014 to Present)

Simultaneously, long-term preclinical safety data revealed a concerning trend: chronic administration of high-dose GLP-1 receptor agonists (specifically liraglutide and semaglutide) caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including malignant medullary thyroid carcinoma (MTC), in rodent models. The human relevance of this finding remains debated within the endocrinology community, as rodents possess vastly higher densities of GLP-1 receptors on their thyroid C-cells compared to primates. Despite the lack of definitive human correlation, the FDA acted with extreme caution, mandating a strict Boxed Warning, the agency's most severe safety labeling, for all long-acting GLP-1RAs. Consequently, these medications are strictly contraindicated in any patient with a personal or familial history of MTC or those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In 2025, the FDA even issued regulatory warning letters to Novo Nordisk and Eli Lilly for promotional television segments that allegedly downplayed the severity of this specific cancer risk.

Gastroparesis, Gallbladder Disease, and the Compounding Crisis (2020 to 2024)

As semaglutide and tirzepatide achieved mass global adoption specifically for weight loss, the core physiological mechanism of the drug — significantly delaying gastric emptying to induce early satiety — began to manifest pathologically in a susceptible subset of patients. Between 2022 and 2024, emergency departments noted a marked increase in severe, intractable gastroparesis, ileus (complete intestinal obstruction), and acute gallbladder disease (cholelithiasis and cholecystitis) associated with rapid weight loss. Furthermore, anesthesiologists reported alarming cases of pulmonary aspiration during general anesthesia in patients actively taking GLP-1s, as retained solid gastric contents regurgitated during intubation despite standard pre-operative fasting. In 2024, the FDA officially updated the labels across the entire class to explicitly warn against use in patients with severe pre-existing gastroparesis and to advise the formal cessation of GLP-1 therapy prior to elective surgeries requiring deep sedation.

Compounding this physiological risk was an unprecedented regulatory and distribution crisis. Severe supply chain shortages from 2022 to 2024 allowed compounding pharmacies (operating under Section 503A and 503B of the FD&C Act) to legally produce non-branded, customized copies of semaglutide and tirzepatide to meet explosive consumer demand. The FDA Adverse Event Reporting System (FAERS) experienced a massive spike in dosing errors and administration-related reactions specifically linked to compounded GLP-1s. Patients, often receiving care through loosely regulated direct-to-consumer telehealth platforms, frequently miscalculated dosages when drawing raw peptides from non-standardized multi-dose vials using traditional insulin syringes, leading to acute volumetric overdoses, severe hypoglycemia, and profound dehydration-induced acute kidney injury. The FDA initiated border blockades (green list import alerts) against untested active pharmaceutical ingredients to stem the flow of fraudulent medications.

The Suicidal Ideation Investigation and Final Clearance (2023 to 2026)

The most significant regulatory review of recent years involved psychiatric safety signals. Because the central nervous system intimately regulates reward, appetite, and satiety circuits, the psychiatric effects of GLP-1 receptor agonism traversing the blood-brain barrier were scrutinized heavily. In July 2023, the European Medicines Agency (EMA), prompted by the Icelandic medicines agency, initiated an urgent formal investigation into approximately 150 reports of suicidal ideation and self-injury among patients actively using liraglutide and semaglutide.

The FDA concurrently launched a massive evaluation of post-marketing FAERS reports across all incretin agents. After an exhaustive, multi-month review utilizing the vast Sentinel System data network, extensive observational cohorts, and a comprehensive meta-analysis of all large-scale clinical trials, the FDA announced in January 2024 that their preliminary evaluations found absolutely no evidence linking GLP-1RAs to suicidal thoughts or actions. In a landmark regulatory decision in early 2026, the FDA concluded that the statistical risk estimate was effectively zero. The agency formally requested the absolute removal of suicidal behavior and ideation warnings from the labels of all FDA-approved GLP-1 receptor agonists, completely clearing the drug class of this severe psychiatric stigma and allowing for unrestricted prescribing in populations with underlying mood disorders.

Chronological Timeline of Incretin Milestones (1906 to 2026)

A century-plus arc of scientific, regulatory, and commercial milestones defining the incretin class.

Key Opinion Leaders Defining the 2026 Landscape

The transformation of the incretin market represents the collaborative, multi-decade output of academic physiologists and pharmaceutical executives.

Academic and Historical

Industry and Pharmaceutical

Conclusion

The evolution of GLP-1 and the broader incretin therapeutic class represents a paradigm shift in pharmacological science. What began as a confusing physiological anomaly regarding oral glucose tolerance in 1964 has steadily transformed into the most potent pharmacological lever for systemic metabolic regulation in human history. The race to master this complex biological pathway negatively impacted pharmaceutical companies that failed to understand the underlying pharmacokinetics or prioritize tolerability, as evidenced by the historic and modern failures of Pfizer, Sanofi, and GlaxoSmithKline. Conversely, the market has rewarded the strategic foresight, chemical ingenuity, and clinical strategy of Novo Nordisk and Eli Lilly.

As of 2026, the clinical landscape has moved far beyond the initial constraints of peptide delivery and simple glycemic control. With the advent of dual and triple agonists generating near-bariatric surgical levels of weight loss, the approval of highly bioavailable small-molecule oral variants, and expanding indications encompassing cardiovascular survival, chronic kidney disease, and sleep apnea, the incretin class has unequivocally broken the traditional distribution models of healthcare. Moving forward, the strategic mastery of intellectual property thickets, direct-to-consumer distribution models, and massive capital investments in global manufacturing scale will dictate market leadership just as heavily as molecular discovery, ensuring that the legacy of GLP-1 remains the defining medical achievement of the early twenty-first century.